Jordan Alger, MD
Urology · Lone Tree, CONPI 1851786065
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (53.0%), travel and lodging and consulting fees — rather than concentrated in one kind of arrangement. 24 manufacturers reported payments, led by Boston Scientific at 25.2% of the total. 2025 is the largest year on record at $1,410, 2.3 times the $618 reported in 2021.
Across 75 payments — averaging $47.31 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boston Scientific$895
- Procept Biorobotics Corporation$773
- Verathon Inc.$400
- Dendreon Pharmaceuticals LLC$190
- Valencia Technologies Corporation$140
- Progenics Pharmaceuticals, Inc.$138
- plus $1K from 18 others
Across 6 payments — averaging $20,049 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Janssen Research & Development, LLC$120K
What the payments were for
- Consulting fees$40011%
- Travel & lodging$1,18233%
- Food & beverage$1,88153%
- Education$852%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boston Scientific | 9 | $895 |
| Procept Biorobotics Corporation | 6 | $773 |
| Verathon Inc. | 1 | $400 |
| Dendreon Pharmaceuticals LLC | 3 | $190 |
| Valencia Technologies Corporation | 4 | $140 |
| Progenics Pharmaceuticals, Inc. | 3 | $138 |
| Merck | 5 | $107 |
| 180 Medical, Inc. | 4 | $97 |
| Myovant Sciences Inc. | 5 | $92 |
| Olympus America Inc. | 4 | $86 |
| Amgen | 1 | $85 |
| Bayer | 4 | $81 |
| Sumitomo Pharma America, Inc. | 4 | $70 |
| Astellas Pharma US Inc | 3 | $68 |
| AbbVie | 3 | $53 |
| Teleflex LLC | 3 | $46 |
| Pfizer | 2 | $43 |
| Johnson & Johnson | 2 | $42 |
| Laborie Medical Technologies Corp. | 3 | $37 |
| Axonics, Inc. | 1 | $27 |
| Myriad Genetic Laboratories, Inc. | 2 | $24 |
| Accord Healthcare, Inc. | 1 | $20 |
| Tolmar, Inc. | 1 | $17 |
| Urogen Pharma, Inc. | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Lumenis Pulse 120H$723
- AquaBeam Robotic System$714
- NPD Clinical Study$400
- PROVENGE$145
- PYLARIFY$108
How this compares
$3,549 in reported general payments places this provider in the 55th percentile of 225 urology providers in Colorado.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| GemtesaVibegron | 51 | $50,077 |
| MyrbetriqMirabegron | 52 | $45,860 |
| OrgovyxRelugolix | 17 | $43,029 |
| Estradiol | 47 | $4,302 |
| Tamsulosin Hcl | 352 | $4,183 |
| Trospium Chloride ErTrospium Chloride | 19 | $4,041 |
| Methenamine Hippurate | 41 | $3,021 |
| Finasteride | 116 | $1,555 |
| Potassium Citrate ErPotassium Citrate | 14 | $1,486 |
| Alfuzosin Hcl ErAlfuzosin Hcl | 33 | $1,045 |
| Solifenacin Succinate | 17 | $661 |
| Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst | 12 | $652 |
| Ciprofloxacin Hcl | 70 | $344 |
| Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav | 26 | $235 |
| Testosterone Cypionate | 11 | $155 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Sumitomo Pharma America, Inc.Gemtesa, Orgovyx | $70 | $93,10568 claims |
| Astellas Pharma US IncMyrbetriq | $68 | $45,86052 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 225 urology providers in Colorado.
Other urology in Lone Tree
- Suzanne MerrillLone Tree$102K
- Ali SarramLone Tree$76K
- Jason GreenfieldLone Tree$19K
- Lawrence KarshDenver$706K
- Alexandra RogersLafayette$476K
- Derek ZukoskyGolden$442K
- James McBrideDurango$234K
- Damian SorceParker$224K
- John KeferBoulder$68K
- Garrick GreearLongmont$62K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.